These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15505596)

  • 1. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial.
    Méndez-Sánchez N; González V; Chávez-Tapia N; Ramos MH; Uribe M
    Ann Hepatol; 2004; 3(3):108-12. PubMed ID: 15505596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.
    Santos VN; Lanzoni VP; Szejnfeld J; Shigueoka D; Parise ER
    Braz J Med Biol Res; 2003 Jun; 36(6):723-9. PubMed ID: 12792701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
    Traussnigg S; Schattenberg JM; Demir M; Wiegand J; Geier A; Teuber G; Hofmann WP; Kremer AE; Spreda F; Kluwe J; Petersen J; Boettler T; Rainer F; Halilbasic E; Greinwald R; Pröls M; Manns MP; Fickert P; Trauner M;
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):781-793. PubMed ID: 31345778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
    Fan JG; Zhong L; Tia LY; Xu ZJ; Li MS; Wang GL
    World J Gastroenterol; 2005 Apr; 11(15):2346-50. PubMed ID: 15818751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
    Ratziu V; de Ledinghen V; Oberti F; Mathurin P; Wartelle-Bladou C; Renou C; Sogni P; Maynard M; Larrey D; Serfaty L; Bonnefont-Rousselot D; Bastard JP; Rivière M; Spénard J;
    J Hepatol; 2011 May; 54(5):1011-9. PubMed ID: 21145828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ref: Gallstone formation in obese subjects undergoing a weight reduction diet.
    Morán S; Milke P; Rodríguez-Leal G; Uribe M
    Int J Obes Relat Metab Disord; 1998 Mar; 22(3):282-4. PubMed ID: 9539199
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
    Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
    Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of fiber administration in the prevention of gallstones in obese patients on a reducing diet. A clinical trial].
    Morán S; Uribe M; Prado ME; de la Mora G; Muñoz RM; Pérez MF; Milke P; Blancas JM; Dehesa M
    Rev Gastroenterol Mex; 1997; 62(4):266-72. PubMed ID: 9580234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program.
    Shiffman ML; Kaplan GD; Brinkman-Kaplan V; Vickers FF
    Ann Intern Med; 1995 Jun; 122(12):899-905. PubMed ID: 7755224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study.
    Wolfhagen FH; van Hoogstraten HJ; van Buuren HR; van Berge-Henegouwen GP; ten Kate FJ; Hop WC; van der Hoek EW; Kerbert MJ; van Lijf HH; den Ouden JW; Smit AM; de Vries RA; van Zanten RA; Schalm SW
    J Hepatol; 1998 Nov; 29(5):736-42. PubMed ID: 9833911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
    Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
    Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.
    Parés A; Caballería L; Rodés J; Bruguera M; Rodrigo L; García-Plaza A; Berenguer J; Rodríguez-Martínez D; Mercader J; Velicia R
    J Hepatol; 2000 Apr; 32(4):561-6. PubMed ID: 10782903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
    Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
    Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
    Avalueva EB; Tkachenko EI; Skazyvaeva EV; Ivanov SV; Orishak EA; Lapinskiĭ IV
    Eksp Klin Gastroenterol; 2013; (11):26-30. PubMed ID: 24933975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.
    González-Koch A; Brahm J; Antezana C; Smok G; Cumsille MA
    J Hepatol; 1997 Jul; 27(1):143-9. PubMed ID: 9252088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in biliary lipid secretion and cholic acid kinetics induced by diet, diet plus simvastatin and diet plus ursodeoxycholic acid in obese subjects.
    Mazzella G; Cipolla A; Villanova N; Polimeni C; Sipahi A; Parini P; Fusaroli P; Festi D; Roda E
    Ital J Gastroenterol; 1995; 27(8):441-5. PubMed ID: 8775472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.